Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · IEX Real-Time Price · USD
1.325
-0.015 (-1.12%)
Jul 22, 2024, 10:04 AM EDT - Market open
Atossa Therapeutics Employees
Atossa Therapeutics had 12 employees as of December 31, 2023. The number of employees increased by 1 or 9.09% compared to the previous year.
Employees
12
Change (1Y)
1
Growth (1Y)
9.09%
Revenue / Employee
n/a
Profits / Employee
-$2,474,250
Market Cap
170.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
TruBridge | 3,219 |
OrganiGram Holdings | 984 |
Repare Therapeutics | 179 |
Rigel Pharmaceuticals | 147 |
Stereotaxis | 122 |
Adverum Biotechnologies | 121 |
MediWound | 100 |
Syros Pharmaceuticals | 68 |
ATOS News
- 1 hour ago - Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer - GlobeNewsWire
- 19 days ago - Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer - GlobeNewsWire
- 24 days ago - Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer - GlobeNewsWire
- 5 weeks ago - Atossa Set to Join Russell 3000® Index Effective June 28, 2024 - GlobeNewsWire
- 6 weeks ago - Atossa to Present at the Sidoti Small-Cap Investor Conference - GlobeNewsWire
- 7 weeks ago - Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire